Index

Note: Page numbers of article titles are in boldface type.

A
ABT-072, 619
ABT-333, 619
ABT-450, 603
ACH-1625, 604
ACH-2684, 605
ADVANCE study, of telaprevir for HCV infection, 563–565

chronic disease, 520
ANA598, 619
Anemia(s), ribavirin-associated, inosine triphosphate polymorphisms and, in HCV infection, 504–506
Antibody therapy, in HCV management, 646–647
AVL-181, 605–606
AVL-192, 605–606

B
BI 201,335, 603
BMS-650,032, 604
BMS-790052, clinical studies with, 633–635
Boceprevir
described, 522
for chronic HCV infection, 522–525
for treatment-experienced patients who had partial or relapse responses to treatment with previous PEG-IFN-α and ribavirin therapy, studies of, 524–525
for treatment-naïve patients
phase 2 study, 522–523
phase 3 studies, 523–524
for HCV infection, 599–600
chronic infection. See Boceprevir, for chronic HCV infection.
early clinical results, 539–549
phase 1 studies, 539–540
phase 2 studies, 540
phase 3 studies, 544, 548–549
SPRINT 1 study, 540–5444
user’s guide, 537–552
viral resistance to, 549–550
user’s guide for, 537–553
viral resistance to, 525–257
Boceprevir/PEG-IFN-α2b combination study
for HCV infection, 539–540
with and without ribavirin, for HCV infection, 540
C

Caspase inhibitors, for chronic HCV infection, 532
CD4+ T-cell count, HCV/HIV coinfection management and, 589
ChronVac-C, in HCV management, 646
Cyclophilin(s), in HCV management, 643–644
Cyclophilin inhibitors, for chronic HCV infection, 531–532

D

DAAs. See Direct-acting antivirals (DAAs).
Danoprevir, 602
Direct-acting antivirals (DAAs)
   IL28B genotype and, 503
      in HCV infection management, combination studies, 659–662
      DAAs with cyclophilin A inhibitors, 661–662
      efficacy of, 658–659
      genotype dependency in, 658–659
      NS3/4A protease inhibitor and non-nucleoside analogue NS5B polymerase inhibitor, 660–661
      NS3/4A protease inhibitor and NS5A inhibitor, 661
      NS3/4A protease inhibitor and nucleoside analogue NS5B polymerase inhibitor, 659–660
      nucleotide analogue NS5B polymerase inhibitor and NS5A inhibitor with and without ribavirin, 661
      nucleotide analogue polymerase inhibitor and ribavirin, with and without PEG-IFN, 661
      purine and pyrimidine nucleotide analogue NS5B polymerase inhibitor, 661
      rationale for, 657–658
      resistance to, 658–659
      resistance to, prevention strategies, 530

E

EXTEND study, of telaprevir for HCV infection, 567–568
   chronic disease, 522

G

Genetic testing, in HCV infection, 497–513
   IL28B genotype, 498–504. See also IL28B genotype, in HCV infection.
      incorporation into clinical algorithms, 506–508
      inosine triphosphate polymorphisms, 504–506
   GI-5005, in HCV management, 645
   GS-9256, 604–605

H

HCV entry inhibitors, in HCV management, 643
HCV infection. See Hepatitis C virus (HCV) infection.
Hepatitis, non-A, non-B, interferons for, 473–475
Hepatitis C virus (HCV)
described, 597–598
life cycle of, 516, 537, 642–643
molecular biology of, 598
nucleoside analog NS5B polymerase inhibitors of, 611–626. See also Nucleoside analog NS5B polymerase inhibitors.
prevalence of, 597, 611
therapeutic targets of, 516
treatment of. See also specific agents.
protease inhibitors in. See also Protease inhibitors.
viral clearance in, factors affecting, 613–614
virion of, 537
Hepatitis C virus (HCV)/HIV coinfection
described, 585
IL28B genotype in, 502
mortality data, 586
treatment of, 585–596
CD4+ T-cell count and, 589
current, 586–587
duration of, 589–590
factors affecting response to, 587
genetic determinants of response to, 587–588
insulin resistance and, 589
new, 590–592
vitamin D status related to, 588–589
Hepatitis C virus (HCV) infection
acute
in HIV infection, 590
spontaneous clearance in, IL28B genotype and, 503
chronic, treatment of
caspase inhibitors in, 532
combination strategies, 530–531
cyclophilin inhibitors in, 532
emerging therapies in, 515–536
boceprevir, 522–525
protease (NS3/4A) inhibitors, 516–517
telaprevir, 517–522
GI-5005 in, 532
MMP inhibitors in, 532–533
PEG-IFN-gamma in, 531
cure for, without interferon, possibility of, 670–672
disease burden of, 485–487
for treatment-naïve patients, 487–488
genetic testing in, 497–513. See also Genetic testing, in HCV infection.
immune response effects of, 670
incidence of, 483–484
prevalence of, 484–485, 497, 515, 573
seroprevalence of, 627
telaprevir for, user’s guide, 537–552. See also Telaprevir, for HCV infection.
treatment of, 641–656. See also specific agents.
agents affecting immune system in, 644–648
Hepatitis (continued)
  antibody therapy in, 646–647
  chronic hepatitis–related, 491–492
  current, 538–550
  cyclophilins in, 643–644
  described, 641–642
  factors affecting response to, 587
  for naïves, nonresponders, and relapsers, 483–495
  for treatment-experienced patients, 488–491, 573–583
    NS3 protease inhibitors in, 576–581
    overview of, 574–576
  HCV entry inhibitors in, 643
  host-targeted antiviral agents in, 642–644
  IFN-free regimens in, 665–675
  immunomodulators in, 647–648
  interferons in, new agents, 648–649
  mixing and matching drugs in, 657–664
    future directions in, 662–663
    nitazoxanide in, 644
    protease inhibitors in, 538–539
    ribavirin-like molecules in, 649–651
    taribavirin in, 649–651
    vaccines in, 645–646
HIV infection
  acute, HCV in, treatment of, 590
  HCV coinfection with. See Hepatitis C virus (HCV)/HIV coinfection.

I
IDX184, 616
IDX320, 605
IDX375, 620
IL28B genotype
  causal variant in, 504
  clinical uses of, 502–503
  DAAs in, 503
  in HCV infection, 498–504
    acute, for spontaneous clearance, 503
    discovery of, 498–504
    genome-wide association studies, 498–501
    HCV genotype 2/3 and, 502
    incorporation into clinical algorithms, 506–508
    viral kinetics and, 501
    week 4 RVR, 501–502
  in HCV/HIV coinfection, 502
  in liver transplantation, 502–503
  in modulation of interferon response, 667–669
  mechanisms of, 503–504
ILLUMINATE study, of telaprevir for HCV infection, 565–566
  chronic disease, 520–521
Immune response
antiviral suppression effects on, 670
HCV infection effects on, 670
Immunomodulators, in HCV management, 647–648
Inosine triphosphate polymorphisms, in HCV infection
  incorporation into clinical algorithms, 508
  ribavirin-associated anemia and, 504–506
Insulin resistance, HCV/HIV coinfection management and, 589
Interferon(s)
  advances in (1990–2010), 473–482
  described, 646–647
  for non-A, non-B hepatitis, advances in (1990–2010), 473–475
  in HCV management, new agents, 478–479, 648–649
  mechanism of action of, 646–647
  modulation of response to, IL-28B in, 667–669
  new, 478–479, 648–649
  pegylated, advances in (1990–2010), 476–478
  ribavirin and, advances in (1990–2010), 475
Interferon-based therapy. See also Interferon(s).
  advances in (1990–2010), 473–482
Interferon-free regimens, in HCV infection management, 665–675
INX-189, 617

L
Liver transplantation, IL28B genotype in, 502–503

M
Matrix metalloprotease (MMP) inhibitors, for chronic HCV infection, 532–533
MK-5172, 605
MMP inhibitors. See Matrix metalloprotease (MMP) inhibitors.

N
Narlaprevir, 604
Nitazoxanide, in HCV management, 644
NNIs. See Non-nucleoside inhibitors (NNIs).
NNI-Site 1 inhibitors, 617
NNI-Site 2 inhibitors, 617–618
NNI-Site 3 inhibitors, 619
NNI-Site 4 inhibitors, 620
Non-A, non-B hepatitis, interferons for, advances in (1990–2010), 473–475
Non-nucleoside inhibitors (NNIs), 611–626
Non-nucleoside NS5B polymerase inhibitors, 617–620
  ABT-072, 619
  ABT-333, 619
  ANA598, 619
  filibuvir, 617–618
  IDX375, 620
  NNI-Site 1 inhibitors, 617
  NNI-Site 2 inhibitors, 617–618
Non-nucleoside (continued)
  - NNI-Site 3 inhibitors, 619
  - NNI-Site 4 inhibitors, 620
  - tegobuvir, 620
  - VX-222/VCH-222, 618
  - VX-759/VCH-759, 619–620
  - VX-916/VCH-916, 618

NS3 protease inhibitors
  - for HCV infection in treatment-experienced patients, 576–581
  - linear, viral resistance to, 525–527
  - second-generation, 527

NS3/4A serine protease
  - as antiviral target, in HCV infection, 598–599
  - first-wave, 599–600
  - second-wave, 600–606

NS5A polymerase inhibitors, 529

NS5A replication complex inhibitors, 627–639
  - clinical studies with BMS-790052, 633–635
  - described, 627
  - discovery and development of, 629–631
  - in HCV, 631–633
  - in viral replication, 631–633

NS5B polymerase inhibitors, 527–529
  - NIs, 527–528
  - NNIs, 528–529

Nucleoside analog NS5B polymerase inhibitors
  - combination trials, 620–621
  - IDX184, 616
  - INX-189, 617
  - of HCV, 611–617
    - described, 611–612
  - PSI-661, 617
  - PSI-938, 616–617
  - PSI-7977, 615–616
  - RG7128, 614–615

P

Pegylated (PEG) interferon(s), advances in (1990–2010), 476–478

Pegylated (PEG)-interferon-gamma, for chronic HCV infection, 531

Protease inhibitors
  - first-wave NS3/4A serine, 599–600
  - for HCV infection, 538–539
    - chronic disease, 516–517
      - second-wave of, 597–609. See also Protease inhibitors, second-wave.
  - second-wave, 597–609
    - ABT-450, 603
    - ACH-1625, 604
    - ACH-2684, 605
    - AVL-181, 605–606
    - AVL-192, 605–606
BI 201,335, 603
BMS-650,032, 604
danoprevir, 602
discussion of, 606–607
GS-9256, 604–605
IDX320, 605
MK-5172, 605
narlaprevir, 604
NS3/4A serine protease, 598–606
TMC-435, 600–602
vaniprevir, 603–604
PROVE 1 study, of telaprevir for HCV infection, 559–560
chronic disease, 518
PROVE 2 study, of telaprevir for HCV infection, 559–561
chronic disease, 518–519
PROVE 3 study, of telaprevir for HCV infection, 561–562
chronic disease, 519
PSI-661, 617
PSI-938, 616–617
PSI-7977, 615–616

R
REALIZE study, of telaprevir for HCV infection, 566–567
chronic disease, 521–522
RESPOND 2 study, of boceprevir for chronic HCV infection, 524–525
RESPOND study, for HCV infection, 548–549
RG7128, 614–615
Ribavirin
in HCV infection management, role of, 662
interferons and, 475
Ribavirin-like molecules, 649–651

S
SPRINT 1 study, of boceprevir for HCV infection, 540–544
chronic disease, 522–523
SPRINT 2 study
for HCV infection, 544, 548
of boceprevir for chronic HCV infection, 523–525
Sustained virologic response (SVR), viral kinetics and, 669
SVR. See Sustained virologic response (SVR).

T
Taribavirin, in HCV management, 649–651
Tegobuvir, 620
Telaprevir
described, 517–518
for chronic HCV infection, 517–522
alternative dosing regimens, 519–520
Telaprevir (continued)

- for treatment-experienced patients, PROVE 3, 519
- for treatment-experienced patients who failed to achieve SVR with previous
  PEG-IFN-α and ribavirin therapy, 521–522
- for treatment-naïve patients
  - phase 2 studies, 518–519
  - phase 3 studies, 520–521
    - ADVANCE study, 520
    - ILLUMINATE study, 520–521
  - PROVE 1 study, 518
  - PROVE 2 study, 518–519
  - long-term study, 522
  - phase 3 studies, 520–522

- for HCV infection, 599–600
  - chronic disease, 517–522. See also Telaprevir, for chronic HCV infection.
  - described, 568–570
  - phase 1 studies, 557–558
  - phase 2 studies, 558–562
  - phase 3 studies, 563–568
  - user’s guide, 555–571
  - mechanism of action of, 555–556
  - viral resistance to, 525–257

- TG4040, in HCV management, 646
- TMC-435, 600–602
- Transplantation, liver, IL28B genotype in, 502–503

V

Vaccine(s)
- GI-5005, for chronic HCV infection, 532
  - in HCV management, 645–646
- Vaniprevir, 603–604
- Viral clearance, factors affecting, 613–614
- Viral kinetics, SVR and, 669
- Vitamin D, status of, in HCV/HIV coinfection treatment, 588–589
  - VX-222/VCH-222, 618
  - VX-759/VCH-759, 619–620
  - VX-916/VCH-916, 618